Oncolytics Biotech Announces Alignments With U.S. FDA Regarding Design Of Pivotal Trial Of Pelareorep In Combination With Standard-Of-Care Therapy To Treat Metastatic Pancreatic Ductal Adenocarcinoma
Benzinga News 19/11 14:02
ManpowerGroup Anticipates Q1 EPS To Be $0.88-$0.98
ManpowerGroup Inc. MAN | 0.00 |
The guidance includes an estimated unfavorable currency impact of 2 cents and excludes unfavorable operating losses for the run-off of Proservia business estimated at 14 cents. The guidance excludes restructuring costs and any Argentina related impact of non-cash currency translation losses.
